Agenus' average one-year price target was raised to $23.46 per share from $15.81, a 48.39% increase. The update reflects improved analyst expectations for the biotech name, though the article provides no operating or clinical catalyst beyond the target revision. This is constructive for sentiment but likely limited in immediate market impact.
Agenus' average one-year price target was raised to $23.46 per share from $15.81, a 48.39% increase. The update reflects improved analyst expectations for the biotech name, though the article provides no operating or clinical catalyst beyond the target revision. This is constructive for sentiment but likely limited in immediate market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
